The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut

NCT ID: NCT05243979

Last Updated: 2022-02-22

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2022-03-01
• Study Completion Date: 2023-04-01

Brief Summary

To evaluate the relation between thyroid, parathyroid hormones and estimated glomerular filtration rate in chronic kidney disease .

Detailed Description

CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. CKD is classified based on Cause, GFR category (G1-G5), and Albuminuria category (A1-A3) .

The global prevalence of CKD is 13.4%, with 10.6% being stages 3-5 ,Over the past 10 years, the death rate due to CKD has increased by 31.7% .

CKD patients remain sometimes asymptomatic, presenting the complications typical of renal dysfunction only in more advanced stages. Its treatment can be conservative usually in patients with glomerular filtration rate above 15 ml/minute without indications of dialysis or replacement therapy .

In CKD patients the changes of endocrine system levels may arise from several causes as the kidney is the site of degradation & synthesis of many different hormones .

So thyroid and parathyroid hormones dysfunction has been recognized as common co-morbidity that is often diagnosed with CKD .

Thyroid hormone is one of the most important hormones in the human body as it regulates majority of the body's physiological actions .

Parathyroid hormone (PTH) is one of the most important hormones required for the maintenance of calcium and phosphate homeostasis .

Chronic kidney disease metabolic bone disorder (CKD-MBD) among patients with end stage renal disease ranges from 33% to 67%, and its severity tends to increase with the progression of the kidney damage & high mortality rates .

CKD-MBD causes bone abnormalities that affect turnover, volume, mineralization, vascular, linear growth, and density, and soft tissue calcification .

Conditions

Thyroid; Parathyroid Diseases; CKD

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

Group (A)

40 patients with CKD (1-3) not on renal replacement therapy.

DEXA scan

Intervention Type: RADIATION

bone study

Group (B)

40 persons with normal kidney function and GFR ( control ).

No interventions assigned to this group

Interventions

DEXA scan

bone study

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• 1. CKD patients 2. Age (18-80 years) 3. Diabetic nephropathy 4. Hypertensive nephropathy 5. Chronic pyelonephritis 6. Obstructive nephropathy 7. Polycystic kidney 8. Gout nephropathy 9. Nephrosclerosis

Exclusion Criteria

• 1. Patients underage of 18 and above 80 2. Patients with history of thyroidectomy and parathyroidectomy 3. Patients with history of thyroid and parathyroid disease before diagnosis of CKD 4. Malignancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Sara Magdy Ahmed Mohammed

Resident doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Sara Magdy

Role: STUDY_CHAIR

Assiut University

Hanan Mahmoud

Role: STUDY_CHAIR

Assiut University

Nashwa Mostafa

Role: STUDY_CHAIR

Assiut University

Central Contacts

Sara Magdy

Role: CONTACT

dr.sara54.sm@gmail.com

01098777997

References

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. No abstract available.

Reference Type: BACKGROUND

PMID: 32998798 (View on PubMed)

Laible M, Horstmann S, Rizos T, Rauch G, Zorn M, Veltkamp R. Prevalence of renal dysfunction in ischaemic stroke and transient ischaemic attack patients with or without atrial fibrillation. Eur J Neurol. 2015 Jan;22(1):64-9, e4-5. doi: 10.1111/ene.12528. Epub 2014 Aug 4.

Reference Type: BACKGROUND

PMID: 25091540 (View on PubMed)

Banerjee D, Jha V. Vitamin D and Cardiovascular Complications of CKD: What's Next? Clin J Am Soc Nephrol. 2019 Jun 7;14(6):932-934. doi: 10.2215/CJN.12581018. Epub 2019 May 7. No abstract available.

Reference Type: BACKGROUND

PMID: 31064752 (View on PubMed)

Ammirati AL. Chronic Kidney Disease. Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s03-s09. doi: 10.1590/1806-9282.66.S1.3.

Reference Type: BACKGROUND

PMID: 31939529 (View on PubMed)

Kuczera P, Adamczak M, Wiecek A. Endocrine Abnormalities in Patients with Chronic Kidney Disease. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015;36(2):109-18. doi: 10.1515/prilozi-2015-0059.

Reference Type: BACKGROUND

PMID: 27442377 (View on PubMed)

Peters J, Roumeliotis S, Mertens PR, Liakopoulos V. Thyroid hormone status in patients with impaired kidney function. Int Urol Nephrol. 2021 Nov;53(11):2349-2358. doi: 10.1007/s11255-021-02800-2. Epub 2021 Mar 8.

Reference Type: BACKGROUND

PMID: 33682051 (View on PubMed)

Guo Y, Wang Q, Lu C, Fan P, Li J, Luo X, Chen D. New parathyroid function index for the differentiation of primary and secondary hyperparathyroidism: a case-control study. BMC Endocr Disord. 2020 Jan 8;20(1):5. doi: 10.1186/s12902-019-0487-8.

Reference Type: BACKGROUND

PMID: 31914999 (View on PubMed)

Habas E Sr, Eledrisi M, Khan F, Elzouki AY. Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management. Cureus. 2021 Jul 14;13(7):e16388. doi: 10.7759/cureus.16388. eCollection 2021 Jul.

Reference Type: BACKGROUND

PMID: 34408941 (View on PubMed)

Other Identifiers

Thyroid, Parathyroid CKD

Identifier Type: -

Identifier Source: org_study_id